Zai Lab Limited (NASDAQ: ZLAB) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -1.79 | Insider Own | 2.89% | Shs Outstand | 112.92M | Perf Week | 6.46% |
| Market Cap | 2.90B | Forward P/E | - | EPS next Y | -2.13 | Insider Trans | -9.22% | Shs Float | 105.17M | Perf Month | -3.82% |
| Enterprise Value | 2.53B | PEG | - | EPS next Q | -0.56 | Inst Own | - | Short Float | 7.62% | Perf Quarter | 41.36% |
| Income | -188.00M | P/S | 6.45 | EPS this Y | -24.42% | Inst Trans | - | Short Ratio | 7.89 | Perf Half Y | 38.10% |
| Sales | 450.00M | P/B | 4.78 | EPS next Y | 4.37% | ROA | -17.49% | Short Interest | 8.02M | Perf YTD | 45.69% |
| Book/sh | 5.38 | P/C | 4.70 | EPS next 5Y | - | ROE | -27.40% | 52W High | 34.72 -25.98% | Perf Year | -21.12% |
| Cash/sh | 5.47 | P/FCF | - | EPS past 3/5Y | - | ROIC | -29.28% | 52W Low | 15.96 61.03% | Perf 3Y | 1.62% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 28.86% 56.50% | Gross Margin | 56.47% | Volatility | 3.81% 3.24% | Perf 5Y | -81.29% |
| Dividend TTM | - | EV/Sales | 5.63 | EPS Y/Y TTM | 31.15% | Oper. Margin | -58.73% | ATR (14) | 1.07 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.92 | Sales Y/Y TTM | 12.78% | Profit Margin | -41.86% | RSI (14) | 57.01 | Recom | 2.18 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.13 | EPS Q/Q | -24.32% | SMA20 | 0.47% | Beta | 0.74 | Target Price | 53.75 |
| Payout | 0.00% | Debt/Eq | 0.30 | Sales Q/Q | -3.64% | SMA50 | 11.25% | Rel Volume | 0.90 | Prev Close | 25.81 |
| Employees | 1,784 | LT Debt/Eq | 0.02 | Earnings | Nov 05 | SMA200 | 28.21% | Avg Volume | 986.00K | Price | 25.70 |
| IPO Date | Sep 20, 2017 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 32.29% 2.35% | Net Debt/EBITDA | 1.73 | Volume | 887,483 | Change | -0.43% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jan-07-26 | Initiated | UBS | Buy | $35 |
| Jun-30-25 | Reiterated | Leerink Partners | Outperform | $101 → $75 |
| Mar-07-25 | Initiated | Scotiabank | Outperform | $55 |
| Mar-03-25 | Downgrade | B of A Securities | Buy → Neutral | |
| Sep-27-24 | Reiterated | Morgan Stanley | $50 | |
| Apr-21-22 | Reiterated | Leerink Partners | $101 |
Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medical treatments. Their therapeutic portfolio spans oncology, autoimmune conditions, infectious diseases, and neurological disorders. Currently available products in their portfolio include Zejula, a once-daily small-molecule PARP 1/2 inhibitor; Optune, a medical device leveraging tumor treating fields; NUZYRA, an antimicrobial agent for specific acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia; and Qinlock, indicated for gastrointestinal stromal tumors. Beyond its commercial offerings, Zai Lab boasts an extensive pipeline of investigational therapies. These include Odronextamab for various B-cell lymphomas; Repotrectinib, a tyrosine kinase inhibitor targeting ROS1 and TRK pathways in both TKI-naïve and pretreated cancer patients; Margetuximab for breast and gastroesophageal cancers; Adagrasib for KRAS-G12C-mutated solid tumors like NSCLC, colorectal, and pancreatic cancers; and Bemarituzumab for gastric and gastroesophageal junction cancers. Further pipeline candidates encompass CLN-081 for EGFR exon 20 insertion NSCLC; Elzovantinib, an orally available multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab, designed to block PD-1 interactions with its ligands; ZL-2309, an orally active and selective CDC7 kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod, aimed at reducing pathogenic immunoglobulin G antibodies; ZL-1102, a human nanobody against interleukin-17A; KarXT for psychiatric and neurological conditions; ZL-2313 and ZL-2314, both investigational EGFR inhibitors targeting specific mutations; and Sulbactam/durlobactam, intended for serious infections caused by Acinetobacter. Established in 2013, Zai Lab Limited maintains its corporate headquarters in Shanghai, China.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 450 | 460 | 399 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 195 | 191 | 148 | — | — | — | — | — | — | |
| Gross Profit | 253 | 269 | 251 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 281 | 278 | 299 | — | — | — | — | — | — | |
| Research and Development | 238 | 221 | 235 | — | — | — | — | — | — | |
| Other Operating Expense | 0 | -6 | -1 | — | — | — | — | — | — | |
| Operating Income | -263 | -224 | -282 | — | — | — | — | — | — | |
| Interest Expense | 6 | 5 | 2 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 78 | 50 | 27 | — | — | — | — | — | — | |
| Net Income Before Taxes | -191 | -178 | -257 | — | — | — | — | — | — | |
| Income Taxes | -3 | -3 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -188 | -176 | -257 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -188 | -176 | -257 | — | — | — | — | — | — | |
| Net Income | -188 | -176 | -257 | — | — | — | — | — | — | |
| EPS (Recurring) | -1.79 | -1.60 | -2.60 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.79 | -1.60 | -2.60 | — | — | — | — | — | — | |
| EPS (Diluted) | -1.79 | -1.60 | -2.60 | — | — | — | — | — | — | |
| EBITDA | -169 | -158 | -235 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 6.40 | 4.22 | 6.50 | — | — | — | — | — | — | |
| Gross Margin | 56.22 | 58.48 | 62.91 | — | — | — | — | — | — | |
| Operating Margin | -58.44 | -48.70 | -70.68 | — | — | — | — | — | — | |
| Net Margin | -41.78 | -38.26 | -64.41 | — | — | — | — | — | — | |
| Shares Outstanding | 112 | 110 | 99 | — | — | — | — | — | — | |
| Market Capitalization | 2,878 | 1,940 | 2,593 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Chen Yajing | Chief Financial Officer | Aug 19 '26 | Sale | 27.00 | 260 | 7,020 | 35,635 | Aug 21 |
| Chen Yajing | Chief Financial Officer | Aug 14 '26 | Option Exercise | 0.00 | 1,250 | 0 | 36,322 | Aug 18 |
| Lis William | Director | Aug 12 '26 | Sale | 25.00 | 8,506 | 212,650 | 41,931 | Aug 13 |
| Chen Yajing | Chief Financial Officer | Aug 11 '26 | Sale | 25.00 | 619 | 15,475 | 35,072 | Aug 13 |
| Du Ying | Chairperson & CEO | Jul 02 '26 | Option Exercise | 0.00 | 11,048 | 0 | 1,225,749 | Jul 06 |
| GAYNOR RICHARD | Director | Jul 01 '26 | Buy | 19.05 | 1,736 | 33,071 | 80,737 | Jul 06 |
| Du Ying | Chairperson & CEO | Jul 01 '26 | Option Exercise | 0.00 | 18,000 | 0 | 1,221,784 | Jul 06 |
| Du Ying | Chairperson & CEO | Jun 30 '26 | Sale | 18.53 | 7,026 | 130,220 | 1,203,784 | Jul 01 |
| Du Ying | Chairperson & CEO | Jun 29 '26 | Option Exercise | 0.00 | 17,970 | 0 | 1,210,810 | Jul 01 |
| Du Ying | Chairperson & CEO | Jun 26 '26 | Sale | 17.46 | 24,543 | 428,545 | 1,192,840 | Jun 29 |
| Chen Yajing | Chief Financial Officer | Jun 26 '26 | Sale | 17.46 | 2,264 | 39,532 | 35,691 | Jun 29 |
| Edmondson Frazor Titus III | Chief Legal Officer | Jun 26 '26 | Sale | 17.46 | 4,103 | 71,642 | 30,346 | Jun 29 |
| Du Ying | Chairperson & CEO | Jun 25 '26 | Option Exercise | 0.00 | 58,800 | 0 | 1,217,383 | Jun 29 |
| Edmondson Frazor Titus III | Chief Legal Officer | Jun 25 '26 | Option Exercise | 0.00 | 14,600 | 0 | 34,449 | Jun 29 |
| Chen Yajing | Chief Financial Officer | Jun 25 '26 | Option Exercise | 0.00 | 6,250 | 0 | 37,955 | Jun 29 |